HIV

Jamshed Arslan, Pharm D, PhD

By Jamshed Arslan, Pharm. D., PhD.

CD4, also known as Cluster of Differentiation 4, interacts with major histocompatibility complex class II antigens, acts as a receptor for the human immunodeficiency virus and induces the aggregation of lipid rafts. It is expressed in T lymphocytes, B cells, macrophages, granulocytes, dendritic cells and specific regions of the brain.

Perforin, also known as the pore-forming protein, pfp, is a 70 kD cytolytic protein expressed in the cytoplasmic granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells.

Research antibodies have long been used to advance HIV/Aids research, however researchers at the California Institute of Technology have recently published a study [PMID: 22033520] developing a new antibody that may someday be used clinically to neutralize HIV. Beginning with a naturally occurring antibody (NIH45-46) purified from HIV positive patients, the researchers modified the antibody using a technique called structure-based rational design.

Antibody studies into the human immunodeficiency virus (HIV) centre around Gag, a highly complex polyprotein that has so far defied attempts to unravel its complex and varied modes of action. Now, a team from the NIST Center for Neutron Research have revealed a new model which has allowed the protein to be studied in far more clarity. The hope with antibody suppliers is that it will pave the way to understanding many more large, unfathomable proteins.